Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other 1Gynecologic 1

Conditions

Obesity 3Prostatic Neoplasms 2Polycystic Ovary Syndrome 2Pancreatic Neoplasms 1Overweight 1Neoplasms 1Metabolic Syndrome 1Inflammation 1Gastrointestinal Neoplasms 1Endometrial Neoplasms 1Endometrial Hyperplasia 1Dyslipidemias 1Colorectal Neoplasms 1Carcinoma, Hepatocellular 1

Interventions

pembrolizumab 45Paclitaxel 42Carboplatin 34Bevacizumab 18Specimen Handling 17Letrozole 16lenvatinib 13Magnetic Resonance Spectroscopy 12dostarlimab 11Cisplatin 11Biopsy 11Taxes 10olaparib 9Fulvestrant 9Doxorubicin 9abemaciclib 8Megestrol Acetate 8Docetaxel 8durvalumab 7atezolizumab 7Nivolumab 7Gemcitabine 7Blood Specimen Collection 7palbociclib 6Oxaliplatin 6Observation 6Fluorouracil 6niraparib 5Surveys and Questionnaires 5Progestins 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Endometrial Neoplasms × semaglutide × 1 year × Clear all
NCT07462663 2026-05-13

SHAPE-ENDO

Hospital Universitari de Bellvitge

Phase 4 Not yet recruiting
82 enrolled
GynecologicOther

Endometrial Hyperplasia, Neoplasms, Obesity, Endometrial Neoplasms, Overweight

Data powered by HemOnc (CC BY 4.0) Colophon âš¡